Gilgamesh Pharma About Programs Pipeline Team News Partners Contact Clinical-Stage Neuroscience An Epic LeapFor Mental Health Developing innovative new chemical entities that transform the treatment paradigm of psychiatric disease — moving beyond symptom management toward rapid-acting, durable therapies. Our Programs View Pipeline Phase 3 Phase 2 Phase 1 IND Bretisilocin Blixeprodil Neuroplastogens GM-3009 M1/M4 Agonist 5+Clinical Programs NCENovel Chemical Entities MultimodalDiscovery Platform 1×Asset Acquired by AbbVie Our Mission Beyond Symptom Management Current psychiatric treatments often mask symptoms rather than addressing underlying neurobiological roots. Gilgamesh is building a new class of precision therapies that engage the brain's own plasticity mechanisms to produce lasting change. Our deep expertise in medicinal chemistry, combined with an AI-powered translational platform, enables us to design and optimize novel molecules with unprecedented speed — targeting the mechanisms that matter most. "The brain has a remarkable capacity to rewire itself. We are learning to speak its language — with molecules designed not to silence, but to restore." — Jonathan Sporn, MD · Founder & CEO Our Programs Five Therapeutic Frontiers Full Pipeline → 01 Bretisilocin (GM-2505) Short-Acting 5-HT2AR Agonist Acquired by AbbVie Our first asset to advance to Phase 2 — a rapid-acting 5-HT2AR agonist with a 2-hour treatment window. Its acquisition by AbbVie validates our NCE discovery platform. Rapid-Acting2-Hour DurationPhase 2 Depression 02 Blixeprodil (GM-1020) NMDAR Antagonist An orally bioavailable NMDAR antagonist with rapid antidepressant effects and low dissociation — enabling potential at-home use and removing the IV monitoring burden of ketamine. OralRapid-ActingLow DissociationPhase 2 Depression 03 Neuroplastogens Non-Hallucinogenic · AbbVie Partnership A novel series of non-hallucinogenic neuroplastogens promoting structural and functional brain plasticity — developed in partnership with AbbVie for depression and anxiety. Non-HallucinogenicNeuroplasticity Depression & Anxiety 04 GM-3009 Safer Ibogaine Analog Structurally optimized ibogaine analogs with improved cardiac safety and maintained efficacy — addressing opioid use disorder, PTSD, and traumatic brain injury. Cardiac SafetyImproved Efficacy OUD · PTSD · TBI 05 M1/M4 Agonist Muscarinic Receptor Agonist A single oral agent with refined M1/M4 selectivity and a significantly reduced peripheral side effect profile, offering a cleaner therapeutic window for schizophrenia. OralReduced Side Effects Schizophrenia Platform Multi-Modal Discovery Behind Every Program Deep medicinal chemistry expertise combined with computational modeling accelerates our NCE pipeline from concept to clinic. See Full Pipeline → Clinical Pipeline Program Status Five programs spanning depression, anxiety, addiction, and schizophrenia — all novel chemical entities designed in-house. Program Indication Type Discovery IND Enabling Phase 1 Phase 2 Phase 3 Bretisilocin (GM-2505) Short-Acting 5-HT2AR Agonist · Acquired by AbbVie Depression NCE Blixeprodil (GM-1020)NMDAR Antagonist Depression NCE NeuroplastogensNon-hallucinogenic · AbbVie partner Depression & Anxiety NCE GM-3009Safer Ibogaine Analog OUD · PTSD · TBI NCE M1/M4 AgonistMuscarinic Receptor Agonist Schizophrenia NCE Complete Active stage Future Acquired by AbbVie Discovery Platform Where Chemistry Meets Intelligence Our discovery and translational platform integrates medicinal chemistry expertise, neurocircuitry science, and deep neuroscience knowledge to accelerate the creation of novel precision psychiatric therapies. The result: faster NCE identification, richer SAR data, and a compounding competitive advantage — as validated by AbbVie's acquisition of Bretisilocin. Medicinal ChemistryExpert-led SAR campaigns deliver best-in-class selectivity, pharmacokinetics, and safety for each NCE. Translational ScienceA state-of-the-art, neurocircuitry-focused platform that integrates behavioral, electrophysiological, molecular, and machine learning approaches to characterize psychoactive compounds and optimize drug candidates for improved clinical translation. Clinical ExecutionRigorous trial design and hands-on operational expertise translate promising molecules into clear clinical proof-of-concept — as demonstrated by positive Phase 2a results for both bretisilocin and blixeprodil. Leadership World-Class Scientists & Leaders A team of medicinal chemists, inventors, and drug development veterans from top academic and biopharmaceutical institutions, tackling the hardest mental health challenges facing the world today. Jonathan Sporn, MDFounder, CEO 25+ years in drug development at Pfizer and J&J. Assistant Professor of Psychiatry, Columbia University. Founder of Perception Neuroscience (acquired by ATAI Life Sciences). Research at Harvard and NIH. Andrew Kruegel, PhDCo-Founder, CSO Medicinal chemist with 15+ years synthesizing and pate...